Biotech | August 10, 2021
Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
A veteran in cell therapy and oncology commercialisation
A veteran in cell therapy and oncology commercialisation
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
